FDA Issues Warning to Sanofi About API CGMP Deviations, Puts Clinical Hold on Atara Immunotherapies - biopharminternational.com
FDA issued a warning to Sanofi about API CGMP deviations and placed a clinical hold on Atara immunotherapies.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the change text.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA issued a warning to Sanofi regarding API CGMP deviations and placed a clinical hold on Atara immunotherapies.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities.
What you must do
Review your own API CGMP compliance and ensure adherence to FDA regulations to avoid similar enforcement actions.
Deadline
Not specified in the change text.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Supreme Court Temporarily Blocks Ruling Barring Telehealth And Pharmacy Access To Mifepristone - Health Affairs
- FDA Proposes to Eliminate "Adequate Provision" for Broadcast Prescription Drug Advertising - foleyhoag.com
- FDA Warning Letter Cites Significant CGMP Violations at Tom’s of Maine Factory - Happi | Household And Personal Products Industry
- Connecticut Law Imposes New Requirements on Pharmaceutical Manufacturers, Defined to Include Device and Cosmetic Manufacturers, that Employ “Pharmaceutical Sales Representatives” - mintz.com
- Fourth Circuit Holds cGMP Violations Do Not Create False Claims Under Medicare and Medicaid - wilmerhale.com